Legal representatives for individuals in the United Kingdom who experienced thrombosis syndrome with thrombocytopenia post-vaccination revealed that the pharmaceutical company acknowledged this potential complication in legal documentation. While the company maintains its original stance, this admission could significantly impact ongoing litigation.
Recent reports from British media disclosed that the AstraZeneca laboratory, amidst a class action lawsuit in the UK, acknowledged the rare occurrence of a side effect associated with its COVID-19 vaccine. This acknowledgment arises within the context of allegations attributing serious injuries to the vaccine in isolated cases.
The pharmaceutical company had previously outlined the possibility of this adverse effect in exceedingly rare instances in a 2021 publication and asserts its position remains unchanged despite the legal developments.
The lawsuit contends that the vaccine led to severe adverse reactions in certain individuals, profoundly affecting multiple families. AstraZeneca's acknowledgment may pave the way for a compensation agreement potentially amounting to £100 million ($125 million) for the plaintiffs, as reported by The Telegraph.
Vaccination remains a pivotal strategy in combating COVID-19, with various manufacturers, including AstraZeneca, playing a crucial role in global distribution and mitigation efforts.
Initially refuting the claims, the laboratory subsequently admitted, in a legal document submitted to the High Court in February, that its vaccine formulation "can, in very rare cases, cause TTS" (thrombosis syndrome with thrombocytopenia), a condition characterized by blood clotting and low platelet counts.
The High Court received 51 cases from individuals alleging they or their relatives experienced these conditions following vaccination.
A letter from AstraZeneca to lawyers representing one of the claimants, Jamie Scott, initially denied a causal link between the vaccine and TTS. However, the legal document submitted to the court acknowledged the vaccine's potential to cause TTS in rare cases, citing an unknown causal mechanism. It emphasized that TTS could also occur independently of the vaccine.
A study published in BMJ in October 2022 first identified a link between the AstraZeneca vaccine and a condition then termed vaccine-induced immune thrombocytopenia and thrombosis (VITT).
Similarly, a study in The Lancet titled "Very rare thrombosis with thrombocytopenia after the second dose of AZD1222" corroborated reports of TTS following vaccination.
Public Health England reported in May 2021 that two doses of the Oxford/AstraZeneca vaccine were 85% to 90% effective against symptomatic COVID-19 based on real-world data.
The World Health Organization's Global Advisory Committee on Vaccine Safety acknowledged reports of TTS post-vaccination, affirming the vaccine's benefits outweigh the risks in regions with active SARS-CoV-2 transmission.
Attorney Sarah Moore from the Leigh Day firm expressed disappointment at AstraZeneca's delayed acknowledgment of the vaccine's potential to cause severe blood clots, contrasting it with the clinical sector's earlier acceptance.
In response, AstraZeneca reiterated its commitment to patient safety, emphasizing regulatory compliance and the vaccine's overall safety profile based on clinical trials and real-world data. Product information was updated in April 2021 to include the rare possibility of TTS triggering.
0 Comments